Eli Lilly and Company (LLY) Financials

$738.33 +15.76 (+2.18%)

Closing price 03:59 PM Eastern

Extended Trading

$738.68 +0.35 (+0.05%)

As of 07:59 PM Eastern

Annual Income Statements for Eli Lilly and Company

This table shows Eli Lilly and Company's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	10,590	5,240	6,245	5,582	6,194	8,318	3,232	-204	2,738	2,408
Consolidated Net Income / (Loss)	10,590	5,240	6,245	5,582	6,194	8,318	3,232	-204	2,738	2,408
Net Income / (Loss) Continuing Operations	10,590	5,240	6,245	5,582	6,194	4,638	3,151	-86	2,738	2,408
Total Pre-Tax Income	12,680	6,555	6,806	6,156	7,230	5,266	3,680	2,305	3,374	2,790
Total Operating Income	12,899	6,458	7,127	6,357	6,058	4,974	3,535	2,003	3,261	2,689
Total Gross Profit	36,624	27,042	21,912	21,006	19,057	17,598	16,812	15,526	15,512	14,922
Total Revenue	45,043	34,124	28,541	28,318	24,540	22,320	21,493	19,974	21,222	19,959
Operating Revenue	45,043	34,124	28,541	28,318	24,540	22,320	21,493	19,974	21,222	19,959
Total Cost of Revenue	8,418	7,082	6,630	7,313	5,483	4,721	4,682	4,448	5,710	5,037
Operating Cost of Revenue	8,418	7,082	6,630	7,313	5,483	4,721	4,682	4,448	5,710	5,037
Total Operating Expenses	23,725	20,584	14,784	14,649	12,999	12,624	13,277	13,523	12,251	12,232
Selling, General & Admin Expense	8,594	7,403	6,440	6,432	6,121	6,214	5,975	5,982	6,528	6,533
Research & Development Expense	14,271	13,113	8,099	7,901	6,746	5,835	7,035	6,209	5,340	5,331
Restructuring Charge	861	68	245	316	131	576	267	1,332	383	368
Total Other Income / (Expense), net	-219	97	-321	-202	1,172	292	146	302	113	101
Other Income / (Expense), net	-219	97	-321	-202	1,172	292	146	302	113	101
Income Tax Expense	2,090	1,314	562	574	1,036	628	530	2,391	636	382
Basic Earnings per Share	$11.76	$5.82	$6.93	$6.15	$6.82	$8.93	$3.14	($0.19)	$2.59	$2.27
Weighted Average Basic Shares Outstanding	900.61M	900.18M	901.74M	906.96M	907.63M	931.06M	1.03B	1.05B	1.06B	1.06B
Diluted Earnings per Share	$11.71	$5.80	$6.90	$6.12	$6.79	$8.89	$3.13	($0.19)	$2.58	$2.26
Weighted Average Diluted Shares Outstanding	904.06M	903.28M	904.62M	911.68M	912.51M	935.68M	1.03B	1.05B	1.06B	1.07B
Weighted Average Basic & Diluted Shares Outstanding	948.17M	950.16M	950.30M	952.35M	958.43M	956.38M	1.03B	1.07B	1.06B	1.06B
Cash Dividends to Common per Share	$5.40	$4.69	$4.07	$3.53	$3.07	$2.58	$2.25	$2.12	$2.05	$2.00

This table shows Eli Lilly and Company's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	2,759	4,410	970	2,967	2,243	2,190	-57	1,763	1,345	1,938	1,452
Consolidated Net Income / (Loss)	2,759	4,410	970	2,967	2,243	2,190	-57	1,763	1,345	1,938	1,452
Net Income / (Loss) Continuing Operations	2,759	4,410	970	2,967	2,243	2,190	-57	1,763	1,345	1,938	1,452
Total Pre-Tax Income	3,456	5,039	1,588	3,517	2,536	2,509	427	2,089	1,530	2,096	1,566
Total Operating Income	3,695	5,149	1,526	3,715	2,509	2,388	450	2,126	1,494	1,836	1,677
Total Gross Profit	10,504	11,129	9,268	9,133	7,095	7,565	7,639	6,505	5,333	5,754	5,363
Total Revenue	12,729	13,533	11,439	11,303	8,768	9,353	9,499	8,312	6,960	7,302	6,942
Operating Revenue	12,729	13,533	11,439	11,303	8,768	9,353	9,499	8,312	6,960	7,302	6,942
Total Cost of Revenue	2,224	2,404	2,171	2,170	1,674	1,788	1,860	1,807	1,627	1,548	1,579
Operating Cost of Revenue	2,224	2,404	2,171	2,170	1,674	1,788	1,860	1,807	1,627	1,548	1,579
Total Operating Expenses	6,809	5,980	7,742	5,418	4,586	5,178	7,188	4,379	3,839	3,917	3,686
Selling, General & Admin Expense	2,469	2,425	2,100	2,117	1,952	1,925	1,804	1,925	1,749	1,643	1,614
Research & Development Expense	4,305	3,212	5,561	2,866	2,633	3,185	5,384	2,454	2,090	2,236	1,865
Restructuring Charge	35	-	82	435	-	-	0.00	0.00	-	-	207
Total Other Income / (Expense), net	-239	-110	62	-198	27	121	-23	-37	36	260	-111
Other Income / (Expense), net	-239	-110	62	-198	27	121	-23	-37	36	260	-111
Income Tax Expense	697	629	618	550	293	319	485	326	185	159	114
Basic Earnings per Share	$3.07	$4.90	$1.08	$3.29	$2.49	$2.43	($0.06)	$1.96	$1.49	$2.15	$1.61
Weighted Average Basic Shares Outstanding	898.70M	900.61M	901M	900.90M	900.80M	900.18M	899.80M	899.70M	901M	901.74M	900.70M
Diluted Earnings per Share	$3.06	$4.88	$1.07	$3.28	$2.48	$2.42	($0.06)	$1.95	$1.49	$2.14	$1.61
Weighted Average Diluted Shares Outstanding	900.60M	904.06M	905M	904.20M	903.80M	903.28M	899.80M	902.70M	903.30M	904.62M	903.80M
Weighted Average Basic & Diluted Shares Outstanding	947.74M	948.17M	949.32M	950.43M	950.41M	950.16M	949.31M	949.30M	949.27M	950.30M	950.18M

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	450	752	-1,752	161	1,320	-5,661	1,526	1,954	916	-205
Net Cash From Operating Activities	8,818	4,240	7,586	7,366	6,500	4,837	5,525	5,616	4,851	2,965
Net Cash From Continuing Operating Activities	8,818	4,240	7,586	7,366	6,500	4,837	5,525	5,616	4,851	2,965
Net Income / (Loss) Continuing Operations	10,590	5,240	6,245	5,582	6,194	8,318	3,232	-204	2,738	2,408
Consolidated Net Income / (Loss)	10,590	5,240	6,245	5,582	6,194	8,318	3,232	-204	2,738	2,408
Depreciation Expense	1,767	1,527	1,523	1,548	1,324	1,233	1,609	1,567	1,497	1,428
Non-Cash Adjustments To Reconcile Net Income	3,752	2,573	1,543	1,324	-470	-3,589	2,236	1,394	285	753
Changes in Operating Assets and Liabilities, net	-7,291	-5,101	-1,725	-1,088	-548	-1,126	-1,553	2,859	332	-1,624
Net Cash From Investing Activities	-9,302	-7,153	-3,763	-2,868	-2,259	-8,083	1,906	-3,784	-3,139	27
Net Cash From Continuing Investing Activities	-9,302	-7,153	-3,763	-2,868	-2,259	-8,083	1,906	-3,784	-3,139	27
Purchase of Property, Plant & Equipment	-5,058	-3,448	-1,854	-1,310	-1,388	-1,034	-1,211	-1,077	-1,037	-1,066
Acquisitions	-4,294	-4,989	-1,458	-1,416	-1,491	-7,611	-1,808	-1,969	-100	-5,843
Purchase of Investments	-776	-829	-708	-1,013	-370	-290	-950	-8,001	-5,673	-4,069
Divestitures	601	1,604	96	216	-	355	0.00	0.00	-	-
Sale and/or Maturity of Investments	523	700	464	847	887	746	6,062	7,439	3,728	5,230
Other Investing Activities, net	-298	-192	-302	-192	103	-249	-188	-175	-130	5,272
Net Cash From Financing Activities	1,230	3,496	-5,407	-4,131	-3,137	-2,325	-5,905	143	-560	-3,111
Net Cash From Continuing Financing Activities	1,230	3,496	-5,407	-4,131	-3,137	-2,325	-5,905	143	-560	-3,111
Repayment of Debt	-3,007	4,356	-371	-2,201	-2,012	-2,071	-3,580	-995	992	-4,689
Repurchase of Common Equity	-2,500	-750	-1,500	-1,250	-500	-4,400	-4,151	-300	-600	-750
Payment of Dividends	-4,680	-4,069	-3,536	-3,087	-2,687	-2,410	-2,312	-2,192	-2,159	-2,127
Issuance of Debt	11,417	3,959	0.00	2,407	2,062	6,556	2,478	3,630	1,207	4,455
Effect of Exchange Rate Changes	-297	169	-168	-	216	-90	-	-21	-236	-86

This table details how cash moves in and out of Eli Lilly and Company's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-175	-101	145	763	-358	438	-314	-851	1,479	-550	-5.50
Net Cash From Operating Activities	1,666	2,474	3,712	1,466	1,166	-312	2,190	632	1,731	1,663	2,217
Net Cash From Continuing Operating Activities	1,666	2,474	3,712	1,466	1,166	-312	2,190	632	1,731	1,663	2,217
Net Income / (Loss) Continuing Operations	2,759	4,410	970	2,967	2,243	2,190	-57	1,763	1,345	1,938	1,452
Consolidated Net Income / (Loss)	2,759	4,410	970	2,967	2,243	2,190	-57	1,763	1,345	1,938	1,452
Depreciation Expense	463	485	467	414	401	388	411	366	362	375	363
Non-Cash Adjustments To Reconcile Net Income	1,875	228	2,747	523	254	597	1,401	324	250	15	184
Changes in Operating Assets and Liabilities, net	-3,431	-2,649	-472	-2,439	-1,732	-3,486	435	-1,822	-227	-665	218
Net Cash From Investing Activities	-3,352	-1,921	-4,005	-2,199	-1,178	-2,924	-3,081	-459	-689	-944	-955
Net Cash From Continuing Investing Activities	-3,352	-1,921	-4,005	-2,199	-1,178	-2,924	-3,081	-459	-689	-944	-955
Purchase of Property, Plant & Equipment	-1,510	-1,496	-1,351	-1,225	-986	-1,071	-970	-738	-669	-501	-617
Acquisitions	-1,757	-251	-2,820	-1,126	-97	-1,625	-3,031	-98	-235	-465	-35
Purchase of Investments	-197	-182	-295	-157	-142	-275	-151	-234	-169	-169	-255
Sale and/or Maturity of Investments	72	97	100	214	112	69	133	155	343	129	109
Other Investing Activities, net	39	-159	-170	96	-65	-23	-666	457	40	32	-223
Net Cash From Financing Activities	1,380	-225	211	1,556	-311	3,545	572	-1,033	412	-1,141	-1,263
Net Cash From Continuing Financing Activities	1,380	-225	211	1,556	-311	3,545	572	-1,033	412	-1,141	-1,263
Repayment of Debt	-2,535	2,997	-3,137	2,728	-5,595	4,563	1,588	-16	-1,779	-257	-381
Repurchase of Common Equity	-1,200	-2,054	-446	-	0.00	-	-	-	-750	-	-
Payment of Dividends	-1,346	-1,168	-1,171	-1,172	-1,169	-1,018	-1,016	-1,018	-1,017	-884	-882
Issuance of Debt	6,461	-	4,965	-	6,453	-	-	-	3,959	-	-
Effect of Exchange Rate Changes	132	-429	227	-60	-36	129	5.30	9.20	25	-128	-3.60

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	78,715	64,006	49,490	48,806	46,633	39,286	43,908	44,981	38,806	35,569
Total Current Assets	32,740	25,727	18,035	18,452	17,462	13,710	20,550	19,202	15,101	12,574
Cash & Equivalents	3,268	2,819	2,067	3,819	3,657	2,338	7,321	6,536	4,582	3,666
Short-Term Investments	155	109	145	90	24	101	88	1,498	1,457	785
Accounts Receivable	13,275	11,336	8,559	8,127	6,929	5,542	5,777	5,262	4,766	4,072
Inventories, net	7,589	5,773	4,310	3,886	3,980	3,191	3,098	4,458	3,562	3,446
Prepaid Expenses	8,341	5,541	2,947	2,531	2,872	2,539	2,037	1,448	735	604
Other Current Assets	111	150	7.30	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	17,102	12,914	10,144	8,985	8,682	7,873	7,996	8,827	8,253	8,054
Total Noncurrent Assets	28,873	25,366	21,311	21,369	20,489	17,704	15,363	16,952	15,452	14,942
Long-Term Investments	3,216	3,052	2,902	3,213	2,967	1,962	2,005	5,679	5,208	3,647
Goodwill	5,770	4,940	4,073	3,892	3,767	3,679	1,367	4,370	3,973	4,040
Intangible Assets	6,166	6,907	7,207	7,692	7,450	6,618	1,068	4,029	4,358	5,035
Noncurrent Deferred & Refundable Income Taxes	8,001	5,477	2,793	2,489	2,830	2,573	2,614	1,166	-	-
Other Noncurrent Operating Assets	5,720	4,990	4,337	4,083	3,475	2,871	1,825	1,708	1,914	2,221
Total Liabilities & Shareholders' Equity	78,715	64,006	49,490	48,806	46,633	39,286	43,908	44,981	38,806	35,569
Total Liabilities	64,443	53,143	38,714	39,651	40,808	36,587	32,999	33,313	24,725	20,979
Total Current Liabilities	28,377	27,293	17,138	15,053	12,482	11,775	11,888	14,536	10,987	8,230
Short-Term Debt	5,117	6,905	1,501	1,538	8.70	1,499	1,102	3,707	1,937	6.10
Accounts Payable	3,229	2,599	1,931	1,671	1,607	1,405	1,207	1,411	1,349	1,338
Dividends Payable	1,346	1,169	1,017	886	771	672	651	591	548	539
Current Employee Benefit Liabilities	2,094	1,650	1,060	958	997	916	956	998	897	967
Other Current Liabilities	16,591	14,970	11,630	9,873	8,603	7,123	6,886	7,297	6,136	5,020
Total Noncurrent Liabilities	36,067	25,849	21,576	24,599	28,326	24,812	21,111	18,777	13,739	12,749
Long-Term Debt	28,527	18,321	14,738	15,346	16,587	13,818	9,196	9,941	8,368	7,972
Noncurrent Deferred Revenue	4,061	3,849	3,710	3,920	3,838	3,607	3,700	3,777	689	869
Noncurrent Employee Benefit Liabilities	1,301	1,439	1,305	1,954	4,095	3,698	2,802	3,514	2,454	2,160
Other Noncurrent Operating Liabilities	2,178	2,241	1,824	1,644	1,708	1,501	1,358	1,546	2,228	1,747
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Total Equity & Noncontrolling Interests	14,272	10,864	10,775	9,155	5,825	2,699	10,909	11,668	14,081	14,590
Total Preferred & Common Equity	14,192	10,772	10,650	8,979	5,642	2,607	9,829	11,592	14,008	14,571
Total Common Equity	14,192	10,772	10,650	8,979	5,642	2,607	9,832	11,592	14,008	14,571
Common Stock	8,032	7,844	7,516	7,430	7,377	7,284	7,245	6,506	6,329	6,243
Retained Earnings	13,545	10,312	10,043	8,959	7,830	4,920	11,396	13,894	16,046	16,012
Treasury Stock	-50	-44	-51	-53	-56	-61	-69	-76	-81	-90
Accumulated Other Comprehensive Income / (Loss)	-4,322	-4,327	-3,845	-4,343	-6,496	-6,524	-5,729	-5,719	-5,274	-4,581
Other Equity Adjustments	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,010	-3,013	-3,013	-3,013
Noncontrolling Interest	80	92	126	176	184	92	1,080	76	73	19

This table presents Eli Lilly and Company's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	89,389	78,715	75,607	71,875	63,944	64,006	57,916	54,814	53,163	49,490	47,462
Total Current Assets	41,261	32,740	31,415	30,204	25,189	25,727	23,007	21,332	20,811	18,035	17,640
Cash & Equivalents	3,093	3,268	3,369	3,224	2,460	2,819	2,381	2,695	3,546	2,067	2,617
Short-Term Investments	127	155	149	140	126	109	113	135	123	145	125
Accounts Receivable	14,003	13,275	12,052	13,079	10,014	11,336	10,364	9,171	9,022	8,559	8,325
Inventories, net	9,311	7,589	7,460	6,482	6,102	5,773	4,901	4,799	4,545	4,310	3,831
Prepaid Expenses	14,654	8,341	8,251	7,138	6,349	5,541	5,248	4,532	3,575	2,947	2,742
Other Current Assets	72	111	135	142	139	150	-	-	-	7.30	-
Plant, Property, & Equipment, net	18,474	17,102	16,172	14,829	13,624	12,914	11,863	11,277	10,546	10,144	9,311
Total Noncurrent Assets	29,654	28,873	28,020	26,841	25,131	25,366	23,045	22,205	21,805	21,311	20,510
Long-Term Investments	3,223	3,216	3,200	2,878	3,087	3,052	2,692	2,745	2,750	2,902	2,575
Goodwill	5,771	5,770	5,768	5,768	4,940	4,940	4,085	4,079	4,073	4,073	3,892
Intangible Assets	6,012	6,166	6,537	6,636	6,762	6,907	6,782	6,904	7,087	7,207	7,124
Noncurrent Deferred & Refundable Income Taxes	8,573	8,001	7,392	6,655	5,634	5,477	4,575	3,806	3,407	2,793	2,384
Other Noncurrent Operating Assets	6,075	5,720	5,122	4,904	4,708	4,990	4,912	4,672	4,488	4,337	4,536
Total Liabilities & Shareholders' Equity	89,389	78,715	75,607	71,875	63,944	64,006	57,916	54,814	53,163	49,490	47,462
Total Liabilities	73,542	64,443	61,286	58,239	51,046	53,143	46,608	43,665	41,868	38,714	37,296
Total Current Liabilities	30,068	28,377	24,674	27,121	18,598	27,293	21,998	18,915	16,010	17,138	15,653
Short-Term Debt	4,016	5,117	2,074	5,162	1,652	6,905	2,245	662	3.10	1,501	1,745
Accounts Payable	3,442	3,229	2,887	2,925	2,474	2,599	2,435	2,474	2,016	1,931	1,683
Dividends Payable	0.00	1,346	0.00	1,171	0.00	1,169	0.00	1,016	0.00	1,017	0.00
Current Deferred & Payable Income Tax Liabilities	6,176	-	-	-	-	-	1,978	1,234	1,528	-	686
Current Employee Benefit Liabilities	1,114	2,094	1,703	1,168	844	1,650	1,233	868	740	1,060	984
Other Current Liabilities	15,320	16,591	18,010	16,696	13,629	14,970	14,108	12,662	11,723	11,630	10,555
Total Noncurrent Liabilities	43,474	36,067	36,612	31,118	32,448	25,849	24,610	24,750	25,858	21,576	21,643
Long-Term Debt	34,500	28,527	29,045	23,730	24,560	18,321	17,924	18,158	18,881	14,738	14,144
Noncurrent Deferred Revenue	5,371	4,061	3,879	3,497	4,189	3,849	3,468	3,331	3,842	3,710	3,642
Noncurrent Employee Benefit Liabilities	1,316	1,301	1,449	1,420	1,428	1,439	1,312	1,309	1,313	1,305	1,833
Other Noncurrent Operating Liabilities	2,288	2,178	2,239	2,471	2,271	2,241	1,906	1,952	1,823	1,824	1,853
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	15,847	14,272	14,321	13,636	12,897	10,864	11,307	11,149	11,295	10,775	10,166
Total Preferred & Common Equity	15,765	14,192	14,240	13,562	12,812	10,772	11,220	11,064	11,190	10,650	10,070
Total Common Equity	15,765	14,192	14,240	13,562	12,812	10,772	11,220	11,064	11,190	10,650	10,070
Common Stock	7,503	8,032	7,934	7,808	7,604	7,844	7,754	7,542	7,387	7,516	7,423
Retained Earnings	15,100	13,545	13,627	13,178	12,554	10,312	10,310	10,369	10,639	10,043	10,007
Treasury Stock	-50	-50	-33	-33	-33	-44	-45	-45	-45	-51	-51
Accumulated Other Comprehensive Income / (Loss)	-3,775	-4,322	-4,275	-4,379	-4,300	-4,327	-3,785	-3,789	-3,777	-3,845	-4,296
Other Equity Adjustments	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013
Noncontrolling Interest	82	80	81	74	85	92	87	86	105	126	96

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.00%	19.56%	0.79%	15.40%	9.95%	3.84%	7.61%	-5.88%	6.33%	1.75%
EBITDA Growth	78.76%	-2.97%	8.12%	-9.95%	31.63%	22.87%	36.60%	-20.50%	15.48%	-3.69%
EBIT Growth	93.46%	-3.70%	10.57%	-14.86%	37.30%	43.09%	59.67%	-31.69%	20.93%	-7.01%
NOPAT Growth	108.65%	-21.04%	13.44%	11.07%	18.46%	44.78%	4,129.35%	-102.84%	13.98%	9.55%
Net Income Growth	102.08%	-16.08%	11.88%	-9.88%	-25.54%	157.38%	1,683.54%	-107.46%	13.67%	0.75%
EPS Growth	101.90%	-15.94%	12.75%	-9.87%	-23.62%	184.03%	1,747.37%	-107.36%	14.16%	1.35%
Operating Cash Flow Growth	107.96%	-44.10%	2.98%	13.33%	34.38%	-12.45%	-1.62%	15.76%	63.63%	-33.51%
Free Cash Flow Firm Growth	82.11%	-193.35%	36.81%	-14.66%	207.08%	-134.02%	467.12%	-64.21%	211.79%	-206.41%
Invested Capital Growth	36.27%	36.48%	15.72%	19.71%	15.79%	99.37%	-41.23%	-10.92%	-8.81%	64.25%
Revenue Q/Q Growth	10.23%	6.40%	-2.39%	2.02%	5.71%	2.18%	12.42%	-11.11%	1.85%	1.29%
EBITDA Q/Q Growth	22.23%	5.55%	2.28%	-6.68%	10.79%	12.68%	9.73%	-10.06%	10.14%	-1.52%
EBIT Q/Q Growth	24.92%	6.71%	3.92%	-9.27%	12.55%	16.25%	17.03%	-17.84%	15.29%	-2.41%
NOPAT Q/Q Growth	28.86%	7.63%	-1.51%	1.81%	9.45%	4.24%	564.66%	-103.94%	6.23%	5.56%
Net Income Q/Q Growth	26.52%	5.05%	3.51%	-6.54%	11.15%	4.72%	610.95%	-109.17%	12.00%	2.12%
EPS Q/Q Growth	26.59%	5.07%	3.92%	-6.56%	8.64%	8.15%	580.43%	-109.00%	12.17%	2.26%
Operating Cash Flow Q/Q Growth	46.18%	-31.77%	-7.32%	6.45%	-2.23%	11.92%	-5.07%	-4.47%	26.31%	-13.05%
Free Cash Flow Firm Q/Q Growth	85.95%	-323.23%	-9.03%	-30.64%	-36.56%	-163.80%	281,157.01%	-37.81%	136.36%	-118.20%
Invested Capital Q/Q Growth	10.07%	18.97%	10.51%	10.86%	4.63%	-8.97%	-54.60%	-20.48%	-12.88%	0.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.31%	79.25%	76.77%	74.18%	77.66%	78.85%	78.22%	77.73%	73.09%	74.76%
EBITDA Margin	32.07%	23.68%	29.18%	27.20%	34.86%	29.12%	24.61%	19.39%	22.95%	21.13%
Operating Margin	28.64%	18.92%	24.97%	22.45%	24.69%	22.29%	16.44%	10.03%	15.37%	13.47%
EBIT Margin	28.15%	19.21%	23.85%	21.74%	29.46%	23.59%	17.12%	11.54%	15.90%	13.98%
Profit (Net Income) Margin	23.51%	15.36%	21.88%	19.71%	25.24%	37.27%	15.04%	-1.02%	12.90%	12.07%
Tax Burden Percent	83.51%	79.95%	91.75%	90.68%	85.67%	157.97%	87.82%	-8.86%	81.14%	86.32%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	16.49%	20.05%	8.25%	9.32%	14.33%	11.93%	14.39%	103.75%	18.86%	13.68%
Return on Invested Capital (ROIC)	29.15%	19.05%	30.61%	31.72%	33.67%	40.84%	31.26%	-0.58%	18.44%	19.23%
ROIC Less NNEP Spread (ROIC-NNEP)	28.41%	19.53%	28.03%	30.01%	42.67%	141.22%	18.46%	-196.04%	714.44%	16.25%
Return on Net Nonoperating Assets (RNNOA)	55.11%	29.38%	32.05%	42.80%	111.65%	81.41%	-2.63%	-1.01%	0.66%	-3.16%
Return on Equity (ROE)	84.26%	48.43%	62.67%	74.52%	145.32%	122.26%	28.63%	-1.59%	19.10%	16.07%
Cash Return on Invested Capital (CROIC)	-1.55%	-11.80%	16.04%	13.78%	19.03%	-25.54%	83.19%	10.97%	27.65%	-29.40%
Operating Return on Assets (OROA)	17.77%	11.55%	13.85%	12.90%	16.83%	12.66%	8.28%	5.50%	9.07%	7.76%
Return on Assets (ROA)	14.84%	9.23%	12.71%	11.70%	14.42%	20.00%	7.27%	-0.49%	7.36%	6.70%
Return on Common Equity (ROCE)	83.69%	47.95%	61.72%	72.74%	140.62%	111.75%	27.17%	-1.58%	19.04%	16.05%
Return on Equity Simple (ROE_SIMPLE)	74.62%	48.65%	58.64%	62.16%	109.79%	319.09%	32.88%	-1.76%	19.54%	16.53%
Net Operating Profit after Tax (NOPAT)	10,773	5,163	6,539	5,765	5,190	4,381	3,026	-75	2,646	2,322
NOPAT Margin	23.92%	15.13%	22.91%	20.36%	21.15%	19.63%	14.08%	-0.38%	12.47%	11.63%
Net Nonoperating Expense Percent (NNEP)	0.75%	-0.47%	2.58%	1.71%	-9.00%	-100.38%	12.81%	195.46%	-696.00%	2.98%
Return On Investment Capital (ROIC_SIMPLE)	22.48%	14.31%	24.21%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	18.69%	20.75%	23.23%	25.82%	22.34%	21.15%	21.78%	22.27%	26.91%	25.24%
SG&A Expenses to Revenue	19.08%	21.69%	22.57%	22.71%	24.94%	27.84%	27.80%	29.95%	30.76%	32.73%
R&D to Revenue	31.68%	38.43%	28.38%	27.90%	27.49%	26.14%	32.73%	31.08%	25.16%	26.71%
Operating Expenses to Revenue	52.67%	60.32%	51.80%	51.73%	52.97%	56.56%	61.77%	67.70%	57.73%	61.29%
Earnings before Interest and Taxes (EBIT)	12,680	6,555	6,806	6,156	7,230	5,266	3,680	2,305	3,374	2,790
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	14,447	8,082	8,329	7,703	8,554	6,499	5,289	3,872	4,871	4,218
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	49.09	48.48	30.52	27.26	26.15	44.29	11.17	6.86	4.87	5.24
Price to Tangible Book Value (P/TBV)	308.90	0.00	0.00	0.00	0.00	0.00	14.85	24.92	12.01	13.89
Price to Revenue (P/Rev)	15.47	15.30	11.39	8.65	6.01	5.17	5.11	3.98	3.21	3.82
Price to Earnings (P/E)	65.79	99.65	52.05	43.86	23.82	13.88	33.98	0.00	24.90	31.69
Dividend Yield	0.67%	0.78%	1.09%	1.27%	1.83%	2.09%	2.12%	2.75%	3.18%	2.79%
Earnings Yield	1.52%	1.00%	1.92%	2.28%	4.20%	7.21%	2.94%	0.00%	4.02%	3.16%
Enterprise Value to Invested Capital (EV/IC)	16.98	17.31	14.67	12.86	9.53	8.85	15.60	6.53	4.92	5.08
Enterprise Value to Revenue (EV/Rev)	16.07	15.87	11.78	9.00	6.43	5.67	5.20	3.98	3.17	3.82
Enterprise Value to EBITDA (EV/EBITDA)	50.10	67.01	40.37	33.07	18.43	19.46	21.13	20.55	13.82	18.07
Enterprise Value to EBIT (EV/EBIT)	57.08	82.62	49.41	41.39	21.81	24.02	30.37	34.53	19.95	27.32
Enterprise Value to NOPAT (EV/NOPAT)	67.19	104.89	51.42	44.19	30.38	28.87	36.94	0.00	25.43	32.83
Enterprise Value to Operating Cash Flow (EV/OCF)	82.09	127.72	44.33	34.59	24.26	26.15	20.23	14.17	13.87	25.71
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	98.17	101.75	53.75	0.00	13.88	56.05	16.96	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.36	2.32	1.51	1.84	2.85	5.67	0.94	1.17	0.73	0.55
Long-Term Debt to Equity	2.00	1.69	1.37	1.68	2.85	5.12	0.84	0.85	0.59	0.55
Financial Leverage	1.94	1.50	1.14	1.43	2.62	0.58	-0.14	0.01	0.00	-0.19
Leverage Ratio	5.68	5.25	4.93	6.37	10.08	6.11	3.94	3.25	2.59	2.40
Compound Leverage Factor	5.68	5.25	4.93	6.37	10.08	6.11	3.94	3.25	2.59	2.40
Debt to Total Capital	70.22%	69.90%	60.11%	64.84%	74.02%	85.02%	48.56%	53.91%	42.26%	35.35%
Short-Term Debt to Total Capital	10.68%	19.13%	5.56%	5.91%	0.04%	8.32%	5.20%	14.64%	7.94%	0.03%
Long-Term Debt to Total Capital	59.54%	50.77%	54.56%	58.94%	73.98%	76.70%	43.36%	39.27%	34.31%	35.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.17%	0.25%	0.46%	0.67%	0.82%	0.51%	5.09%	0.30%	0.30%	0.08%
Common Equity to Total Capital	29.62%	29.85%	39.42%	34.48%	25.16%	14.47%	46.36%	45.79%	57.44%	64.56%
Debt to EBITDA	2.33	3.12	1.95	2.19	1.94	2.36	1.95	3.52	2.12	1.89
Net Debt to EBITDA	1.87	2.38	1.34	1.27	1.16	1.68	0.17	-0.02	-0.19	-0.03
Long-Term Debt to EBITDA	1.97	2.27	1.77	1.99	1.94	2.13	1.74	2.57	1.72	1.89
Debt to NOPAT	3.12	4.89	2.48	2.93	3.20	3.50	3.40	-181.72	3.89	3.44
Net Debt to NOPAT	2.51	3.73	1.70	1.69	1.92	2.49	0.29	0.88	-0.36	-0.05
Long-Term Debt to NOPAT	2.65	3.55	2.25	2.66	3.20	3.15	3.04	-132.37	3.16	3.43
Altman Z-Score	7.90	6.96	6.37	5.04	3.57	3.14	3.36	2.60	3.19	3.78
Noncontrolling Interest Sharing Ratio	0.68%	1.00%	1.51%	2.40%	3.24%	8.59%	5.11%	0.58%	0.32%	0.11%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.15	0.94	1.05	1.23	1.40	1.16	1.73	1.32	1.37	1.53
Quick Ratio	0.59	0.52	0.63	0.80	0.85	0.68	1.11	0.91	0.98	1.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-572	-3,198	3,425	2,504	2,934	-2,740	8,053	1,420	3,968	-3,549
Operating Cash Flow to CapEx	174.34%	122.99%	409.09%	562.37%	468.30%	467.80%	456.34%	521.51%	503.42%	526.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.60	0.58	0.59	0.57	0.54	0.48	0.48	0.57	0.56
Accounts Receivable Turnover	3.66	3.43	3.42	3.76	3.94	3.94	3.89	3.98	4.80	5.07
Inventory Turnover	1.26	1.40	1.62	1.86	1.53	1.50	1.24	1.11	1.63	1.63
Fixed Asset Turnover	3.00	2.96	2.98	3.21	2.96	2.81	2.56	2.34	2.60	2.49
Accounts Payable Turnover	2.89	3.13	3.68	4.46	3.64	3.61	3.58	3.22	4.25	4.08
Days Sales Outstanding (DSO)	99.72	106.40	106.69	97.03	92.74	92.55	93.73	91.63	76.00	71.99
Days Inventory Outstanding (DIO)	289.67	259.81	225.60	196.31	238.67	243.10	294.56	329.09	223.97	224.11
Days Payable Outstanding (DPO)	126.33	116.72	99.13	81.79	100.25	100.98	102.05	113.25	85.89	89.36
Cash Conversion Cycle (CCC)	263.06	249.50	233.17	211.56	231.17	234.66	286.25	307.47	214.08	206.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	42,623	31,278	22,918	19,804	16,543	14,287	7,166	12,193	13,688	15,009
Invested Capital Turnover	1.22	1.26	1.34	1.56	1.59	2.08	2.22	1.54	1.48	1.65
Increase / (Decrease) in Invested Capital	11,345	8,361	3,114	3,261	2,256	7,121	-5,027	-1,495	-1,322	5,871
Enterprise Value (EV)	723,817	541,565	336,279	254,751	157,672	126,461	111,783	79,588	67,295	76,226
Market Capitalization	696,733	522,228	325,028	244,812	147,541	115,453	109,818	79,578	68,163	76,327
Book Value per Share	$14.95	$11.35	$11.21	$9.39	$5.90	$2.72	$9.28	$10.53	$12.69	$13.15
Tangible Book Value per Share	$2.38	($1.13)	($0.66)	($2.72)	($5.83)	($8.01)	$6.98	$2.90	$5.14	$4.96
Total Capital	47,916	36,089	27,014	26,040	22,421	18,016	21,208	25,315	24,386	22,569
Total Debt	33,644	25,225	16,239	16,885	16,595	15,317	10,299	13,647	10,305	7,979
Total Long-Term Debt	28,527	18,321	14,738	15,346	16,587	13,818	9,196	9,941	8,368	7,972
Net Debt	27,005	19,245	11,125	9,764	9,947	10,916	884	-66	-941	-120
Capital Expenditures (CapEx)	5,058	3,448	1,854	1,310	1,388	1,034	1,211	1,077	964	564
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6,057	2,411	186	1,029	1,308	995	2,355	339	14	-102
Debt-free Net Working Capital (DFNWC)	9,480	5,338	2,397	4,938	4,989	3,434	9,764	8,373	6,052	4,350
Net Working Capital (NWC)	4,363	-1,566	896	3,400	4,981	1,934	8,662	4,666	4,115	4,344
Net Nonoperating Expense (NNE)	183	-77	294	183	-1,004	-3,937	-206	129	-92	-87
Net Nonoperating Obligations (NNO)	28,351	20,415	12,142	10,649	10,718	11,588	-3,743	525	-393	419
Total Depreciation and Amortization (D&A)	1,767	1,527	1,523	1,548	1,324	1,233	1,609	1,567	1,497	1,428
Debt-free, Cash-free Net Working Capital to Revenue	13.45%	7.06%	0.65%	3.64%	5.33%	4.46%	10.96%	1.70%	0.06%	-0.51%
Debt-free Net Working Capital to Revenue	21.05%	15.64%	8.40%	17.44%	20.33%	15.38%	45.43%	41.92%	28.52%	21.80%
Net Working Capital to Revenue	9.69%	-4.59%	3.14%	12.01%	20.30%	8.67%	40.30%	23.36%	19.39%	21.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$11.76	$5.82	$6.93	$6.15	$6.82	$8.93	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	900.61M	900.18M	901.74M	906.96M	907.63M	931.06M	0.00	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	$11.71	$5.80	$6.90	$6.12	$6.79	$8.89	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	904.06M	903.28M	904.62M	911.68M	912.51M	935.68M	0.00	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	948.17M	950.16M	950.30M	952.35M	958.43M	956.38M	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	11,491	5,217	6,764	6,051	5,302	4,888	3,254	2,334	2,956	2,639
Normalized NOPAT Margin	25.51%	15.29%	23.70%	21.37%	21.61%	21.90%	15.14%	11.69%	13.93%	13.22%
Pre Tax Income Margin	28.15%	19.21%	23.85%	21.74%	29.46%	23.59%	17.12%	11.54%	15.90%	13.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	44.20%	77.65%	56.62%	55.30%	43.38%	28.97%	71.53%	-1,074.03%	78.85%	88.33%
Augmented Payout Ratio	67.80%	91.96%	80.64%	77.70%	51.46%	81.86%	199.95%	-1,220.92%	100.77%	119.45%

This table displays calculated financial ratios and metrics derived from Eli Lilly and Company's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.17%	44.68%	20.43%	35.98%	25.98%	28.10%	36.84%	28.12%	-10.88%	-8.73%	2.49%
EBITDA Growth	33.45%	90.70%	145.19%	60.13%	55.22%	17.20%	-56.53%	70.52%	-23.99%	8.13%	18.48%
EBIT Growth	36.28%	100.84%	271.82%	68.38%	65.79%	19.67%	-72.71%	91.48%	-25.51%	13.94%	25.71%
NOPAT Growth	32.95%	116.22%	1,640.76%	74.65%	68.93%	22.78%	-103.89%	69.82%	-41.04%	-5.63%	-7.29%
Net Income Growth	23.02%	101.39%	1,790.42%	68.27%	66.77%	13.01%	-103.95%	85.11%	-29.32%	12.26%	30.77%
EPS Growth	23.39%	101.65%	1,883.33%	68.21%	66.44%	13.08%	-103.73%	85.71%	-29.05%	13.83%	31.97%
Operating Cash Flow Growth	42.85%	893.14%	69.53%	132.03%	-32.62%	-118.76%	-1.23%	-46.60%	-31.41%	-26.48%	35.89%
Free Cash Flow Firm Growth	-54.65%	-8.95%	-104.87%	-244.64%	-321.33%	-343.13%	-325.46%	6.70%	-24.01%	3.13%	-251.68%
Invested Capital Growth	43.32%	36.27%	47.29%	47.40%	40.73%	36.48%	26.78%	20.83%	14.91%	15.72%	16.09%
Revenue Q/Q Growth	-5.94%	18.30%	1.21%	28.91%	-6.26%	-1.53%	14.27%	19.43%	-4.68%	5.19%	6.99%
EBITDA Q/Q Growth	-29.05%	168.76%	-47.73%	33.88%	1.39%	245.56%	-65.86%	29.77%	-23.44%	28.16%	33.94%
EBIT Q/Q Growth	-31.41%	217.22%	-54.84%	38.69%	1.09%	487.27%	-79.55%	36.56%	-27.03%	33.91%	43.51%
NOPAT Q/Q Growth	-34.53%	383.27%	-70.25%	41.23%	6.47%	3,543.80%	-103.37%	36.60%	-22.62%	9.18%	47.14%
Net Income Q/Q Growth	-37.43%	354.48%	-67.30%	32.28%	2.43%	3,914.81%	-103.26%	31.10%	-30.59%	33.48%	52.41%
EPS Q/Q Growth	-37.30%	356.07%	-67.38%	32.26%	2.48%	4,133.33%	-103.08%	30.87%	-30.37%	32.92%	53.33%
Operating Cash Flow Q/Q Growth	-32.67%	-33.35%	153.16%	25.75%	473.84%	-114.25%	246.49%	-63.49%	4.08%	-24.99%	87.33%
Free Cash Flow Firm Q/Q Growth	-68.66%	40.53%	-29.04%	-19.49%	-18.82%	-11.82%	-117.08%	-46.08%	-24.97%	-7.36%	52.40%
Invested Capital Q/Q Growth	12.43%	10.07%	3.38%	12.03%	6.90%	18.97%	3.46%	6.96%	3.67%	10.51%	-1.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.53%	82.24%	81.02%	80.80%	80.91%	80.88%	80.42%	78.26%	76.63%	78.80%	77.25%
EBITDA Margin	30.79%	40.82%	17.97%	34.78%	33.49%	30.97%	8.82%	29.54%	27.18%	33.85%	27.78%
Operating Margin	29.03%	38.05%	13.34%	32.87%	28.62%	25.53%	4.74%	25.57%	21.47%	25.15%	24.15%
EBIT Margin	27.15%	37.23%	13.89%	31.12%	28.92%	26.82%	4.50%	25.13%	21.98%	28.71%	22.55%
Profit (Net Income) Margin	21.68%	32.59%	8.48%	26.25%	25.58%	23.41%	-0.60%	21.21%	19.32%	26.54%	20.91%
Tax Burden Percent	79.84%	87.52%	61.09%	84.36%	88.44%	87.28%	-13.44%	84.41%	87.92%	92.43%	92.73%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	20.16%	12.48%	38.91%	15.64%	11.56%	12.72%	113.44%	15.59%	12.08%	7.57%	7.27%
Return on Invested Capital (ROIC)	27.92%	40.59%	10.25%	34.33%	31.80%	28.06%	-0.87%	27.44%	23.52%	31.06%	33.93%
ROIC Less NNEP Spread (ROIC-NNEP)	27.20%	40.20%	10.44%	33.45%	31.94%	28.71%	-0.84%	27.20%	23.79%	33.17%	32.92%
Return on Net Nonoperating Assets (RNNOA)	49.78%	77.98%	16.04%	51.40%	43.58%	43.19%	-1.01%	36.58%	27.13%	37.93%	37.21%
Return on Equity (ROE)	77.70%	118.57%	26.29%	85.73%	75.37%	71.25%	-1.87%	64.01%	50.66%	68.99%	71.14%
Cash Return on Invested Capital (CROIC)	-7.33%	-1.55%	-12.53%	-14.77%	-12.62%	-11.80%	-3.21%	8.55%	11.45%	16.04%	19.51%
Operating Return on Assets (OROA)	17.36%	23.50%	8.50%	19.12%	17.75%	16.13%	2.74%	14.56%	12.16%	16.67%	13.79%
Return on Assets (ROA)	13.86%	20.57%	5.19%	16.13%	15.70%	14.08%	-0.37%	12.29%	10.69%	15.41%	12.79%
Return on Common Equity (ROCE)	77.25%	117.77%	26.12%	85.18%	74.78%	70.54%	-1.86%	63.37%	50.08%	67.95%	69.99%
Return on Equity Simple (ROE_SIMPLE)	70.45%	0.00%	58.78%	54.14%	47.91%	0.00%	44.46%	58.73%	50.82%	0.00%	59.91%
Net Operating Profit after Tax (NOPAT)	2,950	4,506	932	3,134	2,219	2,084	-61	1,794	1,314	1,697	1,555
NOPAT Margin	23.18%	33.30%	8.15%	27.72%	25.31%	22.28%	-0.64%	21.59%	18.87%	23.25%	22.40%
Net Nonoperating Expense Percent (NNEP)	0.73%	0.40%	-0.19%	0.88%	-0.15%	-0.65%	-0.02%	0.23%	-0.27%	-2.11%	1.01%
Return On Investment Capital (ROIC_SIMPLE)	5.43%	9.40%	-	-	-	5.77%	-	-	-	6.28%	-
Cost of Revenue to Revenue	17.47%	17.76%	18.98%	19.20%	19.09%	19.12%	19.58%	21.74%	23.37%	21.20%	22.75%
SG&A Expenses to Revenue	19.40%	17.92%	18.36%	18.73%	22.27%	20.58%	18.99%	23.16%	25.13%	22.50%	23.25%
R&D to Revenue	33.82%	23.73%	48.61%	25.35%	30.03%	34.06%	56.68%	29.52%	30.03%	30.62%	26.87%
Operating Expenses to Revenue	53.50%	44.19%	67.68%	47.93%	52.30%	55.36%	75.68%	52.68%	55.16%	53.65%	53.10%
Earnings before Interest and Taxes (EBIT)	3,456	5,039	1,588	3,517	2,536	2,509	427	2,089	1,530	2,096	1,566
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,919	5,524	2,055	3,932	2,937	2,897	838	2,455	1,892	2,471	1,928
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	47.18	49.09	56.30	60.28	54.71	48.48	42.79	37.93	27.41	30.52	28.52
Price to Tangible Book Value (P/TBV)	186.79	308.90	414.50	706.14	631.25	0.00	1,358.09	5,155.08	10,155.10	0.00	0.00
Price to Revenue (P/Rev)	15.18	15.47	19.62	21.00	19.51	15.30	14.97	14.22	11.08	11.39	9.82
Price to Earnings (P/E)	66.97	65.79	95.79	111.34	114.19	99.65	96.24	64.58	53.93	52.05	47.60
Dividend Yield	0.65%	0.67%	0.57%	0.54%	0.60%	0.78%	0.82%	0.91%	1.20%	1.09%	1.19%
Earnings Yield	1.49%	1.52%	1.04%	0.90%	0.88%	1.00%	1.04%	1.55%	1.85%	1.92%	2.10%
Enterprise Value to Invested Capital (EV/IC)	16.19	16.98	21.34	22.43	21.58	17.31	18.83	17.04	13.44	14.67	14.36
Enterprise Value to Revenue (EV/Rev)	15.84	16.07	20.22	21.59	20.08	15.87	15.44	14.67	11.53	11.78	10.19
Enterprise Value to EBITDA (EV/EBITDA)	50.29	50.10	69.90	79.24	79.06	67.01	64.67	49.50	41.29	40.37	36.58
Enterprise Value to EBIT (EV/EBIT)	57.05	57.08	81.40	93.47	95.43	82.62	80.62	59.47	50.82	49.41	45.47
Enterprise Value to NOPAT (EV/NOPAT)	67.46	67.19	98.84	113.52	118.94	104.89	103.22	68.02	56.73	51.42	44.86
Enterprise Value to Operating Cash Flow (EV/OCF)	83.28	82.09	136.97	186.31	196.32	127.72	79.67	69.36	47.00	44.33	36.39
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	218.06	125.50	98.17	79.10
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.43	2.36	2.17	2.12	2.03	2.32	1.78	1.69	1.67	1.51	1.56
Long-Term Debt to Equity	2.18	2.00	2.03	1.74	1.90	1.69	1.59	1.63	1.67	1.37	1.39
Financial Leverage	1.83	1.94	1.54	1.54	1.36	1.50	1.19	1.34	1.14	1.14	1.13
Leverage Ratio	5.33	5.68	5.21	5.11	4.84	5.25	4.91	5.14	4.82	4.93	5.28
Compound Leverage Factor	5.33	5.68	5.21	5.11	4.84	5.25	4.91	5.14	4.82	4.93	5.28
Debt to Total Capital	70.85%	70.22%	68.48%	67.94%	67.02%	69.90%	64.08%	62.80%	62.57%	60.11%	60.98%
Short-Term Debt to Total Capital	7.39%	10.68%	4.56%	12.14%	4.22%	19.13%	7.13%	2.21%	0.01%	5.56%	6.70%
Long-Term Debt to Total Capital	63.46%	59.54%	63.92%	55.80%	62.80%	50.77%	56.94%	60.59%	62.56%	54.56%	54.29%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.15%	0.17%	0.18%	0.17%	0.22%	0.25%	0.28%	0.29%	0.35%	0.46%	0.37%
Common Equity to Total Capital	29.00%	29.62%	31.34%	31.89%	32.76%	29.85%	35.65%	36.92%	37.08%	39.42%	38.65%
Debt to EBITDA	2.50	2.33	2.63	2.72	2.87	3.12	2.63	2.15	2.44	1.95	1.95
Net Debt to EBITDA	2.08	1.87	2.06	2.14	2.25	2.38	1.96	1.51	1.61	1.34	1.30
Long-Term Debt to EBITDA	2.24	1.97	2.46	2.24	2.69	2.27	2.34	2.08	2.44	1.77	1.74
Debt to NOPAT	3.35	3.12	3.72	3.90	4.32	4.89	4.20	2.96	3.36	2.48	2.39
Net Debt to NOPAT	2.79	2.51	2.92	3.06	3.39	3.73	3.12	2.08	2.21	1.70	1.59
Long-Term Debt to NOPAT	3.00	2.65	3.47	3.21	4.05	3.55	3.74	2.85	3.36	2.25	2.13
Altman Z-Score	7.13	7.58	8.82	9.43	9.33	6.75	7.03	6.75	5.40	6.06	5.69
Noncontrolling Interest Sharing Ratio	0.58%	0.68%	0.65%	0.64%	0.78%	1.00%	0.85%	1.01%	1.14%	1.51%	1.62%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.37	1.15	1.27	1.11	1.35	0.94	1.05	1.13	1.30	1.05	1.13
Quick Ratio	0.57	0.59	0.63	0.61	0.68	0.52	0.58	0.63	0.79	0.63	0.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11,534	-6,839	-11,499	-8,911	-7,458	-6,277	-5,613	-2,586	-1,770	-1,416	-1,319
Operating Cash Flow to CapEx	110.34%	165.36%	274.81%	119.71%	118.22%	-29.13%	225.65%	85.60%	258.88%	332.08%	359.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.64	0.63	0.61	0.61	0.61	0.60	0.61	0.58	0.55	0.58	0.61
Accounts Receivable Turnover	4.08	3.66	3.65	3.50	3.78	3.43	3.43	3.50	3.29	3.42	3.81
Inventory Turnover	1.16	1.26	1.26	1.33	1.34	1.40	1.57	1.51	1.47	1.62	1.84
Fixed Asset Turnover	3.05	3.00	2.92	2.98	2.97	2.96	3.03	2.89	2.82	2.98	3.21
Accounts Payable Turnover	3.03	2.89	2.93	2.78	3.18	3.13	3.32	3.17	3.59	3.68	4.39
Days Sales Outstanding (DSO)	89.44	99.72	100.11	104.33	96.68	106.40	106.34	104.15	110.90	106.69	95.81
Days Inventory Outstanding (DIO)	313.62	289.67	289.13	274.79	272.55	259.81	232.92	241.93	249.00	225.60	198.02
Days Payable Outstanding (DPO)	120.37	126.33	124.47	131.52	114.93	116.72	109.84	114.97	101.79	99.13	83.17
Cash Conversion Cycle (CCC)	282.69	263.06	264.77	247.59	254.30	249.50	229.41	231.11	258.12	233.17	210.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	47,919	42,623	38,722	37,456	33,436	31,278	26,290	25,411	23,759	22,918	20,738
Invested Capital Turnover	1.20	1.22	1.26	1.24	1.26	1.26	1.36	1.27	1.25	1.34	1.51
Increase / (Decrease) in Invested Capital	14,484	11,345	12,432	12,045	9,677	8,361	5,553	4,380	3,084	3,114	2,874
Enterprise Value (EV)	775,969	723,817	826,258	840,226	721,568	541,565	495,154	432,955	319,252	336,279	297,855
Market Capitalization	743,815	696,733	801,776	817,502	700,944	522,228	480,084	419,623	306,684	325,028	287,188
Book Value per Share	$16.63	$14.95	$14.98	$14.27	$14.22	$11.35	$11.82	$11.66	$11.78	$11.21	$10.60
Tangible Book Value per Share	$4.20	$2.38	$2.04	$1.22	$1.23	($1.13)	$0.37	$0.09	$0.03	($0.66)	($1.00)
Total Capital	54,363	47,916	45,440	42,528	39,109	36,089	31,476	29,969	30,179	27,014	26,054
Total Debt	38,516	33,644	31,120	28,892	26,211	25,225	20,168	18,820	18,884	16,239	15,888
Total Long-Term Debt	34,500	28,527	29,045	23,730	24,560	18,321	17,924	18,158	18,881	14,738	14,144
Net Debt	32,073	27,005	24,401	22,650	20,538	19,245	14,983	13,246	12,464	11,125	10,572
Capital Expenditures (CapEx)	1,510	1,496	1,351	1,225	986	1,071	970	738	669	501	617
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11,989	6,057	5,297	4,881	5,656	2,411	760	249	1,135	186	990
Debt-free Net Working Capital (DFNWC)	15,210	9,480	8,815	8,245	8,242	5,338	3,254	3,078	4,805	2,397	3,732
Net Working Capital (NWC)	11,193	4,363	6,741	3,083	6,591	-1,566	1,009	2,417	4,801	896	1,987
Net Nonoperating Expense (NNE)	191	96	-38	167	-24	-106	-3.12	31	-31	-240	103
Net Nonoperating Obligations (NNO)	32,073	28,351	24,401	23,821	20,538	20,415	14,983	14,262	12,464	12,142	10,572
Total Depreciation and Amortization (D&A)	463	485	467	414	401	388	411	366	362	375	363
Debt-free, Cash-free Net Working Capital to Revenue	24.47%	13.45%	12.96%	12.54%	15.74%	7.06%	2.37%	0.84%	4.10%	0.65%	3.38%
Debt-free Net Working Capital to Revenue	31.04%	21.05%	21.57%	21.18%	22.94%	15.64%	10.14%	10.43%	17.35%	8.40%	12.76%
Net Working Capital to Revenue	22.84%	9.69%	16.50%	7.92%	18.34%	-4.59%	3.15%	8.19%	17.34%	3.14%	6.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.07	$4.90	$1.08	$3.29	$2.49	$2.43	($0.06)	$1.96	$1.49	$2.15	$1.61
Adjusted Weighted Average Basic Shares Outstanding	898.70M	900.61M	901M	900.90M	900.80M	900.18M	899.80M	899.70M	901M	901.74M	900.70M
Adjusted Diluted Earnings per Share	$3.06	$4.88	$1.07	$3.28	$2.48	$2.42	($0.06)	$1.95	$1.49	$2.14	$1.61
Adjusted Weighted Average Diluted Shares Outstanding	900.60M	904.06M	905M	904.20M	903.80M	903.28M	899.80M	902.70M	903.30M	904.62M	903.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	947.74M	948.17M	949.32M	950.43M	950.41M	950.16M	949.31M	949.30M	949.27M	950.30M	950.18M
Normalized Net Operating Profit after Tax (NOPAT)	2,978	4,506	982	3,501	2,219	2,084	315	1,794	1,314	1,697	1,746
Normalized NOPAT Margin	23.40%	33.30%	8.59%	30.97%	25.31%	22.28%	3.32%	21.59%	18.87%	23.25%	25.15%
Pre Tax Income Margin	27.15%	37.23%	13.89%	31.12%	28.92%	26.82%	4.50%	25.13%	21.98%	28.71%	22.55%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	43.74%	44.20%	54.12%	59.60%	68.77%	77.65%	78.90%	58.51%	64.49%	56.62%	56.76%
Augmented Payout Ratio	77.05%	67.80%	59.45%	59.60%	68.77%	91.96%	93.93%	70.05%	77.68%	80.64%	94.06%

Frequently Asked Questions About Eli Lilly and Company's Financials

When does Eli Lilly and Company's financial year end?

According to the most recent income statement we have on file, Eli Lilly and Company's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Eli Lilly and Company's net income changed over the last 9 years?

Eli Lilly and Company's net income appears to be on an upward trend, with a most recent value of $10.59 billion in 2024, rising from $2.41 billion in 2015. The previous period was $5.24 billion in 2023. Check out Eli Lilly and Company's forecast to explore projected trends and price targets.

What is Eli Lilly and Company's operating income?

Eli Lilly and Company's total operating income in 2024 was $12.90 billion, based on the following breakdown:

Total Gross Profit: $36.62 billion
Total Operating Expenses: $23.73 billion

How has Eli Lilly and Company revenue changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's total revenue changed from $19.96 billion in 2015 to $45.04 billion in 2024, a change of 125.7%.

How much debt does Eli Lilly and Company have?

Eli Lilly and Company's total liabilities were at $64.44 billion at the end of 2024, a 21.3% increase from 2023, and a 207.2% increase since 2015.

How much cash does Eli Lilly and Company have?

In the past 9 years, Eli Lilly and Company's cash and equivalents has ranged from $2.07 billion in 2022 to $7.32 billion in 2018, and is currently $3.27 billion as of their latest financial filing in 2024.

How has Eli Lilly and Company's book value per share changed over the last 9 years?

Over the last 9 years, Eli Lilly and Company's book value per share changed from 13.15 in 2015 to 14.95 in 2024, a change of 13.7%.

Related Companies

This page (NYSE:LLY) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Financials

Frequently Asked Questions About Eli Lilly and Company's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eli Lilly and Company (LLY) Financials

Annual Income Statements for Eli Lilly and Company

Quarterly Income Statements for Eli Lilly and Company

Annual Cash Flow Statements for Eli Lilly and Company

Quarterly Cash Flow Statements for Eli Lilly and Company

Annual Balance Sheets for Eli Lilly and Company

Quarterly Balance Sheets for Eli Lilly and Company

Annual Metrics And Ratios for Eli Lilly and Company

Quarterly Metrics And Ratios for Eli Lilly and Company

Frequently Asked Questions About Eli Lilly and Company's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools